Literature DB >> 3104916

Pseudomonas exotoxin coupled to a monoclonal antibody against ovarian cancer inhibits the growth of human ovarian cancer cells in a mouse model.

M C Willingham, D J FitzGerald, I Pastan.   

Abstract

In an effort to devise an alternative treatment for human ovarian cancer, we have isolated a monoclonal antibody (OVB-3) that reacts with all ovarian cancers tested (10/10) but few normal tissues. An immunotoxin produced by coupling OVB-3 to Pseudomonas exotoxin kills ovarian cancer cells in tissue culture and prolongs the life of animals bearing human ovarian cancers. These data suggest that this immunotoxin should be evaluated as a treatment for ovarian cancer in women.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3104916      PMCID： PMC304674          DOI： 10.1073/pnas.84.8.2474

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   12.779


  10 in total

Review 1.  Immunotoxins.

Authors:  I Pastan; M C Willingham; D J FitzGerald
Journal:  Cell       Date:  1986-12-05       Impact factor: 41.582

2.  Characterization of a membrane-associated 3,3',5-triiodo-L-thyronine binding protein by use of monoclonal antibodies.

Authors:  S Hasumura; S Kitagawa; E Lovelace; M C Willingham; I Pastan; S Cheng
Journal:  Biochemistry       Date:  1986-12-02       Impact factor: 3.162

3.  Monoclonal antibody specific for avian sarcoma virus structural protein p27.

Authors:  N D Richert
Journal:  J Gen Virol       Date:  1982-10       Impact factor: 3.891

4.  Transferrin receptor on endothelium of brain capillaries.

Authors:  W A Jefferies; M R Brandon; S V Hunt; A F Williams; K C Gatter; D Y Mason
Journal:  Nature       Date:  1984 Nov 8-14       Impact factor: 49.962

5.  A simple method for polyethylene glycol-promoted hybridization of mouse myeloma cells.

Authors:  M L Gefter; D H Margulies; M D Scharff
Journal:  Somatic Cell Genet       Date:  1977-03

6.  Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice.

Authors:  T C Hamilton; R C Young; K G Louie; B C Behrens; W M McKoy; K R Grotzinger; R F Ozols
Journal:  Cancer Res       Date:  1984-11       Impact factor: 12.701

7.  Transferrin receptors in human tissues: their distribution and possible clinical relevance.

Authors:  K C Gatter; G Brown; I S Trowbridge; R E Woolston; D Y Mason
Journal:  J Clin Pathol       Date:  1983-05       Impact factor: 3.411

8.  Epidermal growth factor receptor. Characterization of a monoclonal antibody specific for the receptor of A431 cells.

Authors:  N D Richert; M C Willingham; I Pastan
Journal:  J Biol Chem       Date:  1983-07-25       Impact factor: 5.157

9.  Antitumor effects of an immunotoxin made with Pseudomonas exotoxin in a nude mouse model of human ovarian cancer.

Authors:  D J FitzGerald; M C Willingham; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 12.779

10.  Characterization of immunotoxins active against ovarian cancer cell lines.

Authors:  R Pirker; D J FitzGerald; T C Hamilton; R F Ozols; W Laird; A E Frankel; M C Willingham; I Pastan
Journal:  J Clin Invest       Date:  1985-09       Impact factor: 19.456
  10 in total
  13 in total

Review 1.  Targeted kill: from umbrellas to monoclonal antibodies.

Authors:  V S Byers; R W Baldwin
Journal:  J Clin Immunol       Date:  1992-11       Impact factor: 8.317

2.  A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins.

Authors:  V K Chaudhary; J K Batra; M G Gallo; M C Willingham; D J FitzGerald; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205

3.  Alkylating agents and immunotoxins exert synergistic cytotoxic activity against ovarian cancer cells. Mechanism of action.

Authors:  Y J Lidor; K C O'Briant; F J Xu; T C Hamilton; R F Ozols; R C Bast
Journal:  J Clin Invest       Date:  1993-11       Impact factor: 14.808

Review 4.  Immunotoxins against solid tumors.

Authors:  R Pirker
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

5.  Modification of monoclonal antibody carbohydrates by oxidation, conjugation, or deoxymannojirimycin does not interfere with antibody effector functions.

Authors:  M Awwad; P G Strome; S C Gilman; H R Axelrod
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

6.  Cerebellar Purkinje cells incorporate immunoglobulins and immunotoxins in vitro: implications for human neurological disease and immunotherapeutics.

Authors:  Kenneth E Hill; Susan A Clawson; John W Rose; Noel G Carlson; John E Greenlee
Journal:  J Neuroinflammation       Date:  2009-10-29       Impact factor: 8.322

7.  Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein.

Authors:  P Garin-Chesa; I Campbell; P E Saigo; J L Lewis; L J Old; W J Rettig
Journal:  Am J Pathol       Date:  1993-02       Impact factor: 4.307

8.  Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichia coli.

Authors:  H Lorberboum-Galski; D FitzGerald; V Chaudhary; S Adhya; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

9.  A human hybrid hybridoma producing a bispecific monoclonal antibody that can target tumor cells for attack by Pseudomonas aeruginosa exotoxin A.

Authors:  S Honda; Y Ichimori; S Iwasa
Journal:  Cytotechnology       Date:  1990-07       Impact factor: 2.040

10.  A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells.

Authors:  D J FitzGerald; M C Willingham; C O Cardarelli; H Hamada; T Tsuruo; M M Gottesman; I Pastan
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 12.779
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.